When cancer treatment is mentioned, most people think of it like a nightmare. However, innovative scientists like Clay Siegall have played a significant role towards changing the situation. Siegall became aware of cancer through his father who struggled with it for about five years. During the time, oncologists faced great challenges associated with limited tools for cancer treatment, and this made it hard for patients to survive.
From the experience, Clay got an urge to carry out research and improve facilities in future in order to save the lives of desperate cancer patients. His goal has been to introduce innovative and effective cancer treatment therapies and to alleviate their suffering through targeted cancer drugs. His achievements in the industry have increased through the establishment of partnerships and collaborating with other professionals, innovators, scientists, and leaders.
Clay Siegall dreams of making a difference through improved cancer treatment started when he enrolled to study Genetics and Zoology. He holds a Doctorate in Genetics from the University of George Washington and a Bachelor of Science degree in Zoology from Maryland. His career started at a pharmaceutical research institute under Bristol-Myers Squib before he joined the National Cancer Institute and the National Institutes of Health.
He has served as one of the Board of Directors at Ultragenyx Pharmaceutical, Alder Biopharmaceutical, and Washington Roundtable. Clay’s dream became a reality when he founded Seattle Genetics in 1998 and chose to put into practice the knowledge and skills he had gained from the previous roles. Currently, he is the Chief Executive Officer of the celebrated Seattle Genetics. The company focuses on research and development of cancer therapies.
Under clay’s leadership, Settle Genetics has laid the foundation for enhanced cancer treatment through scientific innovation, extensive research, and drug advancement. For instance, Seattle Genetics in collaboration with Takeda Pharmaceuticals Company developed effective antibody-drug conjugates. The drug attained the FDA approval in 2011, and it is now a global brand accessible in more than 65 countries worldwide. As more firms involved in cancer research and treatment discover the effectiveness of Seattle’s ADC technology, many of them are seeking to enter into agreements with Clay Siegall and Seattle Genetics to further development.